Skip to main content

GW Pharma's marijuana-derived epilepsy drug sales continue to climb

GW Pharmaceuticals Inc. reported revenue that topped the consensus estimates Tuesday, as the company’s marijuana-derived epilepsy drug continue to grow.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.